Benign symmetrical lipomatosis (peripheral lipodystrophy) during antiretroviral treatment of HIV infection;Benigne symmetrische lipomatose ('peripheral lipodystrophy') bei antiretroviraler therapie der HIV-infektion

Deutsche Medizinische Wochenschrift

Volumn 123, Issue 50, 1998, Pages 1512-1516

  Fischer, Th ^a,b   Schworer H ^a,b   Ramadori, G ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CASE REPORT; CYTOLOGY; ECHOGRAPHY; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPOMATOSIS; LOW FAT DIET; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HEMOPHILIA A;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HEMOPHILIA A; HIV INFECTIONS; HUMANS; INDINAVIR; LIPOMATOSIS, MULTIPLE SYMMETRICAL; MALE; ZALCITABINE; ZIDOVUDINE;

EID: 0032509025     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024217     Document Type: Article

References (19)

1. Braun-Falco, O. (Hrsg.): Dermatologie und Venerologie. 4. Auflg. (Springer: Heidelberg 1996), 1381.
2. Carr, A., K. Samaras, D. J. Chisholm, D. A. Cooper: Pathogenesis of HIV 1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 352 (1998), 1881-1883.
3. Enzi, G., C. Agnelli, P. Negrin, M. Armani: Sensory, motor, and autonomic neuropathy in patients with multiple symmetric lipomatosis. Medicine 64 (1986), 380.
4. Grunfeld, C., M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, K.R. Feingold: Lipids, lipoproteins, triglycerid clearance, and cytokines in human immunodeficiency virus infection. J. clin. Endocrinol. 74 (1993), 1045-1052.
5. Hengel, R. L., N. B. Watts, J. L. Lennox: Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350 (1997), 1596.
6. Klopstock, T.: Multiple symmetric lipomatosis in complex 4 and multiple deletions in mitochondrial DNA. Neurology 44 (1984), 862-866.
7. Kovács, A., C. Klein: Madelung-Krankheit. Chirurg 68 (1997), 276-279.
8. Leung, N.J. Gaer, D. Beggs: Multiple symmetric lipomatosis. Clin. Endocrinol. 27 (1987), 601-606.
9. Lo, J. C., K. Mulligan, V. W. Tai, H. Algren, M. Schambelan: »Buffalo hump« in men with HIV-1 infection. Lancet 351 (1998), 867-870.
10. Miller, D. B., J. D. Spence: Clinical Pharmacokinetics of fibric acid derivatives (Fibrates). Clin. Pharmacokinet. 34 (1998), 155-162.
11. Miller, K. D., E. Jones, J. A. Yanovski, R. Shankar, I. Feuerstein, J. Falloon: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351 (1998), 871-875.
12. von Moltke, L. L., D. J. Greenblatt, J. M. Grassi, B. W. Granda, S. X. Duan, S. M. Fogelman, J. P. Daily, J. S. Harnatz, R. I. Shader: Protease Inhibitors as inhibitors of human cytochrome P450: High risk associated with Ritonavir. J. clin. Pharmacol. 38 (1998), 106-111.
13. Murray, M., M. D. Lumpkin: FDA Public Health Advisory: reports of diabetes and hyperglycermia in patients receiving protease inhibitors for the treatment of HIV. Bethesda. MD: Food and Drug Administration, 1997.
14. Peeke, P.M., G. P. Chrousos: Hypercortisolism and obesity. Ann. N. Y. Acad. Sci. 771 (1995), 665-676.
15. Pfannenschmidt, N., K. Jäger: Reduktionsplastik bei benigner symmetrischer Lipomatose. Z. Hautkr. 65 (1990), 838-841.
16. th ed. (WB Saunders: Philadelphia 1995), 345-357.
17. Sehouli, J., D. Stengel, H. Schauwecker: Bénigne symmetrische Lipomatose - Therapeutisches Dilemma. Langenbecks Arch. Chir. 382 (1997), 271-273.
18. Transon, C., T. Leemann, P. Dayer: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2 C9, CYP2 D6 and CYP3 A4) by HMG-CoA reductase inhibitors. Eur. J. clin. Pharmacol. 50 (1996), 209-215.
19. Wesslau, C.: Coupling between the beta-adrenergic receptor and the adenylate-cyclase-pathophysiological implications. Acta med. scand. Suppl. 672 (1993), 17-20.